Clinical Trial Update: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Xaluritamig in high-risk biochemically recurrent, non-metastatic castration-sensitive prostate cancer (Amgen-sponsored). The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Castration-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xaluritamig (Xaluritamig)

Snippet

Sponsor: Amgen | Conditions: Prostate Cancer, High-risk Biochemical Recurrence | Phase 1 | Status: ACTIVE_NOT_RECRUITING